The clinical trial conducted by Merck Sharp & Dohme LLC evaluates the safety and efficacy of sitagliptin compared to sulfonylureas in managing hypoglycemia during Ramadan fasting in patients with Type 2 Diabetes Mellitus. Given the significant Muslim population that observes Ramadan, this study addresses a critical need in diabetes management, potentially expanding sitagliptin's market share in regions with high fasting prevalence. The results may enhance Merck's competitive positioning against other diabetes therapies, particularly sulfonylureas, which are widely used but carry a higher risk of hypoglycemia. The findings could also inform marketing strategies and educational initiatives aimed at healthcare providers and patients in these demographics.